How the LCY Evidence Meter Works

The LCY Evidence Meter is a communication framework, not a numerical score or medical recommendation. It tells readers how closely a published claim is supported by relevant evidence and which uncertainties remain visible.

Strong

Strong is reserved for a consistent body of relevant human evidence: usually several well-designed studies or high-quality syntheses, clinically meaningful outcomes, adequate follow-up and results that are not dependent on one sponsor, laboratory or narrow population. Important limitations can remain, but they do not overturn the central finding.

Moderate

Moderate means the direction of evidence is reasonably supported but confidence is reduced by factors such as limited replication, smaller samples, mixed outcomes, short duration, indirect comparisons or incomplete independence. It is more than a promising signal and less than a settled conclusion.

Early

Early identifies a plausible and relevant signal from preliminary human work, a small controlled study, a single dataset or evidence that has not yet been independently repeated. Preclinical or laboratory findings can explain a mechanism, but they do not by themselves establish a consumer outcome.

Insufficient and Marketing Claim

Insufficient means the available material cannot answer the specific claim with relevant evidence. Marketing Claim describes provenance: the support supplied is mainly promotional, testimonial or brand-controlled. It does not automatically mean false, but it cannot be upgraded without better evidence.

How a comparison is graded

The desk records population, product or intervention, comparator, outcome, duration, geography, data owner, funding and declared conflicts. Studies are not pooled informally when those elements are too different. A statistically visible change is also checked for practical or clinical relevance.

Limitations, updates and corrections

Evidence grades can change when stronger studies, safety communications or corrected data appear. Articles state search and publication dates where relevant, explain important exclusions and distinguish an LCY interpretation from a source's own conclusion.

What the meter does not do

The meter cannot decide whether an intervention is right for an individual, replace product instructions or override regulatory and medical advice. A high evidence grade for one outcome does not validate every claim made for the same ingredient, device or brand.

Commercial transparency

Evidence grades cannot be purchased. Advertisers, sponsors, affiliate partners and featured brands are assessed under the same criteria, with commercial relationships labelled separately.

Reproducible decision rules

LCY rates a defined claim–outcome pair, not an ingredient, device, company or category in the abstract. The assessment record must state the population, product or intervention, comparator, outcome, duration, geography, data owner, funding and declared conflicts. If two sources study materially different formulations, endpoints or populations, they are described side by side rather than blended into a false comparison.

Strong requires direct and relevant human evidence with either credible independent replication or a high-quality synthesis, broadly consistent findings and no major unresolved concern about bias, indirectness, imprecision or safety. Moderate requires meaningful human support but retains at least one material limitation, such as a single independent study, short follow-up, mixed outcomes or incomplete generalisability. These are LCY operational labels; they are not a validated clinical scale.

Early is used for a plausible preliminary signal, including a small or single study, sponsor-controlled evidence, surrogate outcomes or a result that has not been replicated. Insufficient means the available material cannot answer the exact claim. Marketing Claim identifies the provenance of support as mainly promotional or testimonial; it is not a declaration that the claim is false.

A grade can move downward when the evidence is inconsistent, indirect, imprecise, selectively reported or financially dependent on one source. It can move upward only when new evidence addresses the stated limitation. Trend momentum, retailer distribution and search interest are evaluated separately from efficacy, safety and clinical relevance.

Method sources: scope, contribution and limits

Cochrane Handbook, Chapter 14: certainty by outcome

This Cochrane methods chapter explains how GRADE assesses certainty for a body of evidence one outcome at a time. It identifies five core reasons for lower confidence: risk of bias, inconsistency, indirectness, imprecision and publication bias. It also requires reviewers to explain their judgments rather than presenting a label without an audit trail.

For LCY, the practical contribution is the discipline of attaching a grade to the precise outcome being discussed. Evidence that a formula changes a hydration measurement does not automatically establish wrinkle reduction, long-term benefit or superiority over another product. The same source may therefore support different grades for different claims.

The chapter does not supply a universal score for cosmetics, devices, fashion signals or commercial launches, and LCY does not claim to perform a formal GRADE review in every article. Certainty is also not the same as effect size, personal suitability or absence of harm. LCY adapts the transparent domains while stating when evidence is outside a clinical-review context.

Primary methods source: Cochrane Handbook, Chapter 14 (updated May 2025) (opens in a new tab)

PRISMA 2020: transparency of a systematic review

The PRISMA 2020 statement is a peer-reviewed reporting guideline for systematic reviews. Its checklist and flow structure ask authors to disclose the review question, eligibility criteria, information sources, search and selection process, synthesis methods, risk-of-bias assessment and the handling of certainty, among other items.

LCY uses those reporting elements to judge whether a review can be traced and interpreted. A review that names databases, search dates, exclusions and synthesis decisions gives readers a clearer route to reproduce the evidence trail than a review that presents only a pooled headline.

PRISMA is a reporting guideline, not a guarantee that a review was well designed or that its conclusion is correct. Complete reporting cannot repair biased primary studies, inappropriate pooling or an irrelevant endpoint. LCY therefore treats PRISMA-style transparency as one input and still checks study relevance, bias, consistency and applicability.

Primary peer-reviewed source: PRISMA 2020 statement, BMJ 2021;372:n71 (opens in a new tab)

ICMJE Recommendations: disclosure and editorial independence

The ICMJE Recommendations describe disclosure of financial and non-financial relationships across authors, reviewers and editors. They ask authors to identify sources of support and explain the sponsor's role in study design, data collection, analysis, interpretation, writing and publication restrictions.

For LCY, this means funding, employment, consultancy, patents, brand ownership and other relevant relationships are recorded separately from the scientific result. Commercial sponsorship, branded content and affiliate arrangements are labelled in the publication layer and cannot purchase a higher evidence grade.

Disclosure does not prove that a study is biased, and the absence of a declared relationship does not prove independence. A disclosed relationship becomes more consequential when it coincides with design limitations, selective reporting, lack of independent replication or sponsor control. LCY reports the relationship and the methodological concern separately so readers can judge both.

Primary editorial-standard source: ICMJE disclosure recommendations (current recommendations page) (opens in a new tab)

Safety, limitations and commercial relationship

The Evidence Meter communicates the strength and limits of published information; it does not diagnose, prescribe or decide whether a product or procedure is appropriate for an individual. Readers should follow product instructions and applicable regulatory or professional guidance, especially for devices, invasive procedures, pregnancy, medicines, allergies or persistent symptoms.

LifeCareYou does not sell products. No sponsorship, affiliate relationship or member discount code is attached to this methodology update, and the three sources above were selected for editorial-method relevance. Future commercial relationships must remain visibly separate from evidence grading.